THE EXPERT BOARD'S ABSTRACT ON QUESTIONS OF THE SURVIVAL OF BIOLOGICAL AGENTS AND THE POSSIBILITY OF SWITCHING TO SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE
.
Saved in:
Main Author: | artilce Editorial |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2017-04-01
|
Series: | Научно-практическая ревматология |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2369 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
by: S. K. Zyryanov, et al.
Published: (2017-04-01) -
THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-12-01) -
The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01) -
Aortitis in ankylosing spondylitis: the possibilities of diagnosis and treatment
by: А А Годзенко, et al.
Published: (2013-11-01) -
Some features of osteogenesis in ankylosing spondylitis and the possibilities of treatment with bisphosphonates
by: A. V. Datsina, et al.
Published: (2024-06-01)